&Robin Spark Communication Grant
We believe bold ideas deserve bold communication
The grant includes strategic and creative support to help build a strong communication foundation. This covers consultancy on communication strategy (e.g. disease awareness, GTM strategy), as well as the development of core brand essentials such as visual identity, core story and messaging. In other words, you’ll work closely with our team of strategists, writers and designers to start your communication journey.
The SPARK Grant is an in-kind contribution of up to DKK 250,000 over one year. That means the grant is redeemed through &Robin’s services, not as direct funding.
We’re looking for early-stage companies addressing SDG 3 (Good Health and Well-being) with smart solutions that will make a real difference in people’s lives, and who are ready to communicate their vision with clarity and confidence.
Applications for the 2026 Spark Communication Great will open on November 1st. Check back for application guidelines. Follow us on LinkedIn for Spark Grant announcements.
“A key challenge for healthcare startups is helping laymen audiences understand the value of their idea. The Spark Grant is one way we help early-stage companies with bold ideas build the communication foundation they need to secure investment and go forward to create real impact”
Alan Emmins, Partner and Communication Consultant
Meet the 2025 Recipient
&Robin has awarded its first ever SPARK Communication Grant to Copenhagen-based healthcare start-up, Sylvia Health.
Sylvia Health aims to transform pelvic organ prolapse treatment for millions of women around the globe. The founders, Andrew Stretton and Nikolaj Ulrik Friis, became aware of the profound impact pelvic organ prolapse has on women’s quality of life during clinical observations at the obstetrics and gynaecology departments of Slagelse Hospital.
It’s symptomatic for 1 in 12 women, but an even larger number is undiagnosed or living with asymptomatic prolapse – that’s over 200 million worldwide – and the number is growing. Despite its widespread prevalence, pelvic organ prolapse often goes overlooked, and current treatment options fall short.
Sylvia Health secured funding from the Danish Innovation Fund in 2024, which enabled the initiation of product development. Medical grade prototypes are currently undergoing rigorous testing, and feedback from users and clinicians is positive.
The collaboration with &Robin and Sylvia Health marks an important step on the road towards product commercialisation, with the potential to help millions of women worldwide.
Find out more about Sylvia Health at https://sylviahealth.dk
